Published in Clin Infect Dis on May 01, 2011
Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT) (ADEPTT) | NCT03302299
Corticosteroids/β2-agonists in Hair in Asthmatic Patients (CorticHair) (CorticHair) | NCT03691961
Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men | NCT04772469
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses (2012) 1.89
Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial. PLoS One (2015) 1.41
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One (2014) 1.35
Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2011) 1.18
A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis (2012) 1.17
Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya. J Acquir Immune Defic Syndr (2014) 1.16
γ-H2AX and other histone post-translational modifications in the clinic. Biochim Biophys Acta (2012) 1.07
Short communication: A low-cost method for analyzing nevirapine levels in hair as a marker of adherence in resource-limited settings. AIDS Res Hum Retroviruses (2013) 1.06
Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr (2013) 1.05
Reactions, beliefs and concerns associated with providing hair specimens for medical research among a South African sample: a qualitative approach. Future Virol (2012) 0.98
Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda. J Clin Pharmacol (2013) 0.97
Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women. AIDS (2015) 0.97
Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures. J Acquir Immune Defic Syndr (2015) 0.96
Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics (2014) 0.95
Antiretroviral bioanalysis methods of tissues and body biofluids. Bioanalysis (2013) 0.94
Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women. AIDS (2015) 0.94
Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States. AIDS (2013) 0.92
Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. Antimicrob Agents Chemother (2013) 0.92
Implementation and Operational Research: Pulling the Network Together: Quasiexperimental Trial of a Patient-Defined Support Network Intervention for Promoting Engagement in HIV Care and Medication Adherence on Mfangano Island, Kenya. J Acquir Immune Defic Syndr (2015) 0.88
HIV-Infected Individuals Who Delay, Decline, or Discontinue Antiretroviral Therapy: Comparing Clinic- and Peer-Recruited Cohorts. Front Public Health (2014) 0.88
Assessment of HIV antiretroviral therapy adherence by measuring drug concentrations in hair among children in rural Uganda. AIDS Care (2014) 0.88
Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women. AIDS Res Hum Retroviruses (2014) 0.87
Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children. AIDS Res Hum Retroviruses (2015) 0.87
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients. PLoS One (2015) 0.83
Behavioral intervention improves treatment outcomes among HIV-infected individuals who have delayed, declined, or discontinued antiretroviral therapy: a randomized controlled trial of a novel intervention. AIDS Behav (2015) 0.82
Analysis of Antiretrovirals in Single Hair Strands for Evaluation of Drug Adherence with Infrared-Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging. Anal Chem (2015) 0.81
Strong Correlation between Concentrations of Antiretrovirals in Home-Collected and Study-Collected Hair Samples: Implications for Adherence Monitoring. J Acquir Immune Defic Syndr (2017) 0.77
HIV PrEP Trials: The Road to Success. Clin Investig (Lond) (2013) 0.77
The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral Drugs. Front Immunol (2016) 0.76
Menstrual cycle phase and single tablet antiretroviral medication adherence in women with HIV. AIDS Care (2015) 0.75
Lamivudine Concentration in Hair and Prediction of Virologic Failure and Drug Resistance among HIV Patients Receiving Free ART in China. PLoS One (2016) 0.75
Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis. PLoS One (2016) 0.75
Cohort for Tuberculosis Research by the Indo-US Medical Partnership (CTRIUMPH): protocol for a multicentric prospective observational study. BMJ Open (2016) 0.75
Hair Measurements of Cortisol, DHEA, and DHEA to Cortisol Ratio as Biomarkers of Chronic Stress among People Living with HIV in China: Known-Group Validation. PLoS One (2017) 0.75
Measuring the efficacy of antiretroviral therapy. Int J Trichology (2012) 0.75
Isoniazid hair concentrations in children with tuberculosis: a proof of concept study. Int J Tuberc Lung Dis (2016) 0.75
Using the multiphase optimization strategy (MOST) to optimize an HIV care continuum intervention for vulnerable populations: a study protocol. BMC Public Health (2017) 0.75
Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics (2017) 0.75
CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women. AIDS Res Hum Retroviruses (2016) 0.75
Defining a cut-off for atazanavir in hair samples associated with virological failure among adolescents failing second-line antiretroviral treatment. J Acquir Immune Defic Syndr (2017) 0.75
Brief Report: Lopinavir Hair Concentrations are the Strongest Predictor of Viremia in HIV-infected Asian Children and Adolescents on Second-line Antiretroviral Therapy. J Acquir Immune Defic Syndr (2017) 0.75
A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi. BMC Infect Dis (2017) 0.75
The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology (1998) 12.32
The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther (2008) 4.00
Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr (2006) 3.93
Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials (2004) 3.75
Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS (2006) 2.57
Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures. Clin Infect Dis (2010) 2.32
Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr (2011) 1.98
"White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials (2008) 1.68
Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS (2009) 1.68
Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clin Infect Dis (2010) 1.49
Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom (2008) 1.44
Hair as a biological specimen for therapeutic drug monitoring. Int J Clin Pract (2001) 1.40
Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort. HIV Med (2010) 1.29
Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol (2005) 1.28
Hair it is: the long and short of monitoring antiretroviral treatment. Ann Intern Med (2002) 1.22
Management of antiretroviral failure and resistance in developing countries. Curr Opin HIV AIDS (2009) 1.00
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. HIV Med (2010) 0.86
Risk of high-level viraemia in HIV-infected patients on successful antiretroviral treatment for more than 6 months. HIV Med (2010) 0.82
Factors predictive of virological failure on atazanavir in 310 HIV-infected patients. AIDS (2010) 0.82
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A (2009) 8.25
Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science (2007) 6.04
Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol (2003) 5.81
Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science (2005) 5.50
Age affects outcomes in chronic kidney disease. J Am Soc Nephrol (2007) 5.36
Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health (2008) 5.32
Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst (2005) 5.29
Association of journal quality indicators with methodological quality of clinical research articles. JAMA (2002) 5.13
Competing risk regression models for epidemiologic data. Am J Epidemiol (2009) 4.75
Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation. BMJ (2013) 4.17
Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med (2010) 4.07
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS (2008) 3.66
The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proc Natl Acad Sci U S A (2008) 3.65
Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Med (2008) 3.64
Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis (2003) 3.63
Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med (2008) 3.57
Human tRNA-derived small RNAs in the global regulation of RNA silencing. RNA (2010) 3.40
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis (2011) 3.38
Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. J Infect Dis (2004) 3.17
Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS (2009) 3.12
Transfusion-related acute lung injury: incidence and risk factors. Blood (2011) 3.12
High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol (2005) 3.10
The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med (2004) 3.05
3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med (2004) 2.96
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int (2002) 2.83
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82
Rapid HIV-1 testing during labor: a multicenter study. JAMA (2004) 2.81
Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst (2003) 2.81
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr (2007) 2.73
Physician predictors of mammographic accuracy. J Natl Cancer Inst (2005) 2.72
C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med (2006) 2.67
Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis (2007) 2.67
Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health (2004) 2.66
Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis (2004) 2.66
Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology (2005) 2.63
Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS (2003) 2.60
Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis (2007) 2.55
Effect of brief safer-sex counseling by medical providers to HIV-1 seropositive patients: a multi-clinic assessment. AIDS (2004) 2.55
Atlas - a data warehouse for integrative bioinformatics. BMC Bioinformatics (2005) 2.51
Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med (2013) 2.47
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr (2010) 2.47
Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol Biomarkers Prev (2005) 2.45
Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS (2005) 2.42
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol (2010) 2.41
Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer (2007) 2.37
Changes in stress, eating, and metabolic factors are related to changes in telomerase activity in a randomized mindfulness intervention pilot study. Psychoneuroendocrinology (2011) 2.37
Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med (2007) 2.36
Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest (2008) 2.35
Geography matters: relationships among urban residential segregation, dialysis facilities, and patient outcomes. Ann Intern Med (2007) 2.33
Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol (2002) 2.32
Driving status and risk of entry into long-term care in older adults. Am J Public Health (2006) 2.32
Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr (2002) 2.30
Adherence to antiretroviral therapy and its association with sexual behavior in a national sample of women with human immunodeficiency virus. Clin Infect Dis (2002) 2.29
Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS (2008) 2.28
Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis (2013) 2.23
Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst (2004) 2.23
Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol (2005) 2.20
Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health (2006) 2.19
The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol (2007) 2.19
Diagnosis and treatment of abdominal cocoon: a report of 24 cases. Am J Surg (2009) 2.19
Effect of emergency department crowding on time to antibiotics in patients admitted with community-acquired pneumonia. Ann Emerg Med (2007) 2.18
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health (2004) 2.18
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17
Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol (2004) 2.17
White/black racial differences in risk of end-stage renal disease and death. Am J Med (2009) 2.16
Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. J Infect Dis (2012) 2.16
Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. Am J Public Health (2002) 2.15